Predicine has partnered with Apollomics to develop PredicineCARE, a sequencing test for detecting non-small cell lung cancer (NSCLC).
PredicineCARE received Breakthrough Device Designation (BDD) from the US FDA in August 2022. This cfDNA blood-based assay is claimed to be capable of examining mutations/indels, fusions, amplifications, and deletions in vital cancer-related genes using cfDNA extracted from liquid biopsy samples like blood and urine.
Predicine is a molecular insights company specializing in its liquid biopsy technology. The company focuses on non-invasive cancer profiling and monitoring, using cfDNA and cfRNA to detect and monitor cancer. Predicine's proprietary platforms, such as PredicineATLAS and PredicineBEACON, offer genomic profiling, aiding in early cancer detection, treatment selection, and monitoring of therapy response and disease progression.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.